, Volume 1, Issue 4, pp 296-302
Date: 23 Aug 2007

COX-2, NSAIDs, and cardiovascular risk

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Clinical studies of selective and nonselective inhibitors of cyclooxygenase-2 (COX-2) provide evidence that inhibition of the enzyme is associated with modestly increased risks of cardiovascular thrombotic events. Investigation of the physiology of COX-2 demonstrates a complex array of interlinked factors affecting its regulation and function. Efficient integration of data from the basic sciences and randomized and observational studies is necessary to fully understand the consequences of COX-2 inhibition and thereby provide guidance for the safe use of COX-2-inhibiting drugs.